Literature DB >> 18590961

Antileukemic activity of aminoparthenolide analogs.

Shama Nasim1, Peter A Crooks.   

Abstract

A series of aminoparthenolide analogs have been synthesized through a diastereoselective conjugate addition of several primary and secondary amines to the alpha-methylene-gamma-butyrolactone function of the very lipophilic sesquiterpene lactone, parthenolide. Seventeen of the above amines derivatives were evaluated in a full panel of 60 cancer cell lines for anticancer activity. Compound 12, derived from tyramine, was found to be cytostatic as well as cytotoxic toward acute lymphoblastic leukemia cells (ALL, CCRF-CEM) at nanomolar concentrations, while the (R)-(1,2,3,4-tetrahydro-1-naphthyl)amino derivative 9 was found to be cytostatic toward human anaplastic large T-cell lymphoma (SR) cells at concentrations below 10 nM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18590961     DOI: 10.1016/j.bmcl.2008.06.050

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  30 in total

1.  Microbial transformation of the sesquiterpene lactone tagitinin C by the fungus Aspergillus terreus.

Authors:  Bruno Alves Rocha; Mônica Tallarico Pupo; Gilmara Ausech Antonucci; Suely Vilela Sampaio; Raquel de Melo Alves Paiva; Suraia Said; Leonardo Gobbo-Neto; Fernando Batista Da Costa
Journal:  J Ind Microbiol Biotechnol       Date:  2012-07-11       Impact factor: 3.346

2.  Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.

Authors:  Vikas Tyagi; Hanan Alwaseem; Kristen M O'Dwyer; Jessica Ponder; Qi Ying Li; Craig T Jordan; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2016-06-16       Impact factor: 3.641

3.  Heterocyclic aminoparthenolide derivatives modulate G(2)-M cell cycle progression during Xenopus oocyte maturation.

Authors:  Venumadhav Janganati; Narsimha Reddy Penthala; Chad E Cragle; Angus M MacNicol; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2014-03-04       Impact factor: 2.823

4.  Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia.

Authors:  Zaineb A F Albayati; Venumadhav Janganati; Zheng Chen; Jessica Ponder; Philip J Breen; Craig T Jordan; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2016-12-26       Impact factor: 3.641

5.  Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.

Authors:  Joshua N Kolev; Kristen M O'Dwyer; Craig T Jordan; Rudi Fasan
Journal:  ACS Chem Biol       Date:  2013-11-08       Impact factor: 5.100

6.  Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis.

Authors:  Hanan Alwaseem; Benjamin J Frisch; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2017-08-08       Impact factor: 3.641

7.  Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression.

Authors:  Narsimha R Penthala; Shobanbabu Bommagani; Venumadhav Janganati; Kenzie B MacNicol; Chad E Cragle; Nikhil R Madadi; Linda L Hardy; Angus M MacNicol; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2014-08-07       Impact factor: 6.514

8.  Anti-cancer activity of carbamate derivatives of melampomagnolide B.

Authors:  Venumadhav Janganati; Narsimha Reddy Penthala; Nikhil Reddy Madadi; Zheng Chen; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2014-05-27       Impact factor: 2.823

9.  Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells.

Authors:  Shobanbabu Bommagani; Jessica Ponder; Narsimha R Penthala; Venumadhav Janganati; Craig T Jordan; Michael J Borrelli; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2017-05-11       Impact factor: 6.514

10.  MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells.

Authors:  Venumadhav Janganati; Jessica Ponder; Meenakshisundaram Balasubramaniam; Poornima Bhat-Nakshatri; Eli E Bar; Harikrishna Nakshatri; Craig T Jordan; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2018-08-10       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.